Millot, F.; Suttorp, M.; Ragot, S.; Leverger, G.; Dalle, J.-H.; Thomas, C.; Cheikh, N.; Nelken, B.; Poirée, M.; Plat, G.;
et al. Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML. Cancers 2021, 13, 4102.
https://doi.org/10.3390/cancers13164102
AMA Style
Millot F, Suttorp M, Ragot S, Leverger G, Dalle J-H, Thomas C, Cheikh N, Nelken B, Poirée M, Plat G,
et al. Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML. Cancers. 2021; 13(16):4102.
https://doi.org/10.3390/cancers13164102
Chicago/Turabian Style
Millot, Frédéric, Meinolf Suttorp, Stéphanie Ragot, Guy Leverger, Jean-Hugues Dalle, Caroline Thomas, Nathalie Cheikh, Brigitte Nelken, Marilyne Poirée, Geneviève Plat,
and et al. 2021. "Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML" Cancers 13, no. 16: 4102.
https://doi.org/10.3390/cancers13164102
APA Style
Millot, F., Suttorp, M., Ragot, S., Leverger, G., Dalle, J.-H., Thomas, C., Cheikh, N., Nelken, B., Poirée, M., Plat, G., Versluys, B., Lausen, B., & Borisevich, M.
(2021). Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML. Cancers, 13(16), 4102.
https://doi.org/10.3390/cancers13164102
